Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients

Phase 2

Alnylam Pharmaceuticals